MarjorieR on Nostr: nprofile1q…s60lz as well as misuse of antibiotics there is a big problem on that ...
nprofile1qy2hwumn8ghj7un9d3shjtnddaehgu3wwp6kyqpqg0tuf634rz4suczwj7kgnecr6cyt0eu9xmp3sp0fku68mqehq4msas60lz (nprofile…60lz) as well as misuse of antibiotics there is a big problem on that there is currently no money for big pharma in developing new ones.
From the article:
"The ease with which AMR spreads means it is becoming more and more important that we do not misuse the antibiotics we possess. It also generates a need for new antibiotics to be developed - and again this raise problems, said Davies.
'We’ve had no new classes of antibiotics come into routine use since the late 80s and the market model that would promote the creation of new ones is broken. If you develop a new antibiotic, it might be used by someone for a weekly course once a year. Where’s the profit in that?'
'By contrast, blood pressure drugs that have to be taken every day, or cancer drugs that have to be administered for months, offer pharmaceuticals far greater profits. So there is no incentive for them to try to develop new antibiotics. It is a real headache.'
The problems that lie ahead in dealing with AMR are not insurmountable, Davies insists, but they must be addressed with an increased sense of urgency. The G7 forum of industrialised nations has at least recognised the crisis. However, there is still a lack of adequate action and that needs to be tackled as an imperative in the coming year, she insists."
Again Government funding needed?
And for goodness sake if we do that reserve the patent rights.
From the article:
"The ease with which AMR spreads means it is becoming more and more important that we do not misuse the antibiotics we possess. It also generates a need for new antibiotics to be developed - and again this raise problems, said Davies.
'We’ve had no new classes of antibiotics come into routine use since the late 80s and the market model that would promote the creation of new ones is broken. If you develop a new antibiotic, it might be used by someone for a weekly course once a year. Where’s the profit in that?'
'By contrast, blood pressure drugs that have to be taken every day, or cancer drugs that have to be administered for months, offer pharmaceuticals far greater profits. So there is no incentive for them to try to develop new antibiotics. It is a real headache.'
The problems that lie ahead in dealing with AMR are not insurmountable, Davies insists, but they must be addressed with an increased sense of urgency. The G7 forum of industrialised nations has at least recognised the crisis. However, there is still a lack of adequate action and that needs to be tackled as an imperative in the coming year, she insists."
Again Government funding needed?
And for goodness sake if we do that reserve the patent rights.